Skip to main content

Table 2 Central composite design for optimization with the measured responses

From: Quality by design approach for development and validation of a RP-HPLC method for simultaneous estimation of xipamide and valsartan in human plasma

Std.

Run

Factor 1

Factor 2

Response 1

Response 2

A: % MeOH

B: Flow rate (mL/min)

Retention time (VAL) (min)

Resolution

12

1

62.5

1.1

5.99

6.23

6

2

66.0355

1.1

4.6

4.18

4

3

65

1.2

4.57

4.77

11

4

62.5

1.1

5.87

6.2

3

5

60

1.2

6.6

7.29

1

6

60

1

8

7.81

13

7

62.5

1.1

5.79

6.11

10

8

62.5

1.1

5.79

6.16

5

9

58.9645

1.1

7.68

8.48

9

10

62.5

1.1

5.76

6.16

8

11

62.5

1.24142

5.17

6.09

2

12

65

1

5.45

4.75

7

13

62.5

0.958579

6.6

6.27